title: Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' reply.
authors.affiliation: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.|Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.|State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: G L-H
authors.initials: GL
authors.lastname: Wong
authors.affiliation: Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. wongv@cuhk.edu.hk.|Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. wongv@cuhk.edu.hk.|State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. wongv@cuhk.edu.hk.
authors.forename: V W-S
authors.initials: VW
authors.lastname: Wong
mesh_terms: D000998:Antiviral Agents; D006528:Carcinoma, Hepatocellular; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic; D006801:Humans; D008113:Liver Neoplasms
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens